The gastrointestinal tract is under continuous control of the autonomic nervous system (ANS), with sympathetic and parasympathetic pathways coordinating fundamental aspects of intestinal physiology, including motility, secretion, epithelial barrier function, and immune homeostasis1,2. In the colon, extrinsic sympathetic inputs can exert region-dependent effects across multiple cellular compartments, underscoring that broad ANS perturbations may obscure site-specific intestinal phenotypes1. Conversely, parasympathetic circuits, classically mediated by vagal signaling and downstream cholinergic mechanisms, are increasingly recognized as integral to maintaining intestinal immune balance and shaping mucosal responses, further motivating experimental strategies that can disentangle sympathetic versus parasympathetic contributions with anatomic precision2.
Beyond physiological regulation, autonomic activity has emerged as a relevant modifier of intestinal disease biology, including colorectal cancer (CRC). Recent work in CRC demonstrates a bidirectional sympathetic nerve–mesenchymal program, in which β2-adrenergic signaling and NGF-expressing cancer-associated fibroblasts reinforce neural–stromal interactions and promote tumor progression, providing direct evidence that sympathetic circuits can be functionally coupled to CRC pathogenesis3. In parallel, cholinergic signaling has been linked to CRC growth and tumor-associated immune features, as shown by pharmacologic inhibition of muscarinic receptor 3 in an orthotopic mouse model and by connecting cholinergic signaling with immune checkpoint expression and other malignant hallmarks4,5. Importantly, autonomic influences on intestinal disease may also converge with other modulators, such as psychological stress and the gut microbiota. The enteric nervous system can relay stress signals to intestinal inflammation6, and microbial signals can engage gut–brain circuits that tune gut-extrinsic sympathetic neurons, collectively supporting a multi-factorial framework in which neural regulation intersects with immune and microbial ecology6,7.
These converging lines of evidence highlight the need for experimental approaches that can isolate gut-directed autonomic effects with sufficient anatomical precision to support causal inference across both physiological and pathological settings. Despite rapid progress in circuit mapping and neuromodulation, many commonly used interventions remain limited in organ specificity. Systemic pharmacologic manipulation, chemical sympathectomy, and subdiaphragmatic vagotomy can influence broad autonomic outputs and thereby alter immune and metabolic set points beyond the intestine, complicating causal attribution to colon-specific neural inputs8. For example, vagal circuits can suppress inflammatory cytokine production9, and vagal stimulation can modulate pancreatic endocrine function and β cell dynamics, illustrating that upstream or non-selective interventions may introduce extra-intestinal effects that confound interpretation of intestinal phenotypes10. These limitations are particularly consequential for studies aiming to isolate colon-restricted autonomic mechanisms in physiology and pathology. The overall goal of the method is therefore to enable anatomically guided, selective transection of gut-directed sympathetic and parasympathetic fibers in mice, providing a practical model for interrogating intestinal autonomic regulation with reduced off-target impact.
In summary, this protocol reports a more precise murine intestinal autonomic denervation approach with minimal disruption to the autonomic innervation of other abdominal organs, thereby enhancing interpretability by reducing potential bias from extra-intestinal organ effects.